Cellectar Biosciences: Focusing on Advancing Radiotherapeutic Assets Including Alpha- and Auger-Emitting Radioconjugates Into Phase 1 Solid Tumor Studies >CLRB
Cellectar Biosciences: Focusing on Advancing Radiotherapeutic Assets Including Alpha- and Auger-Emitting Radioconjugates Into Phase 1 Solid Tumor Studies >CLRB
Cellectar BioSciences：專注於推進包括α和奧吉發射放射合劑在內的放射治療資產進入第一階段實體腫瘤研究 >CLRB
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登入免費觀看全文
登入/註冊
資訊熱榜
更新時間